Advanced

Concomitant medication of psychoses in a lifetime perspective

Vares, Maria; Saetre, Peter; Stralin, Pontus; Levander, Sten LU ; Lindstrom, Eva and Jonsson, Erik G. (2011) In Human Psychopharmacology: Clinical and Experimental 26(4-5). p.322-331
Abstract
Objective Patients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness. Methods A retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders. Results Benzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs... (More)
Objective Patients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness. Methods A retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders. Results Benzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs to 86%, and antidepressants to 56% of the patients. However, lifetime doses were small and most of the time patients had no concomitant medication. The prescribed lifetime dose of anti-parkinsonism drugs was associated with that of prescribed first-generation but not second-generation antipsychotics. Conclusions Most psychosis patients are sometimes treated with concomitant drugs but mainly over short periods. Lifetime concomitant add-on medication at the individual patient level is variable and complex but not extensive. Copyright (C) 2011 John Wiley & Sons, Ltd. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
antipsychotic drugs, concomitant medication, schizophrenia, retrospective, poly-pharmacy, lifetime
in
Human Psychopharmacology: Clinical and Experimental
volume
26
issue
4-5
pages
322 - 331
publisher
John Wiley & Sons
external identifiers
  • wos:000293964700007
  • scopus:79960847925
ISSN
0885-6222
DOI
10.1002/hup.1209
language
English
LU publication?
yes
id
cd87a4d6-5b3a-4943-b236-c92f035498b1 (old id 2162024)
date added to LUP
2011-10-03 08:37:17
date last changed
2017-06-25 03:17:35
@article{cd87a4d6-5b3a-4943-b236-c92f035498b1,
  abstract     = {Objective Patients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness. Methods A retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders. Results Benzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs to 86%, and antidepressants to 56% of the patients. However, lifetime doses were small and most of the time patients had no concomitant medication. The prescribed lifetime dose of anti-parkinsonism drugs was associated with that of prescribed first-generation but not second-generation antipsychotics. Conclusions Most psychosis patients are sometimes treated with concomitant drugs but mainly over short periods. Lifetime concomitant add-on medication at the individual patient level is variable and complex but not extensive. Copyright (C) 2011 John Wiley & Sons, Ltd.},
  author       = {Vares, Maria and Saetre, Peter and Stralin, Pontus and Levander, Sten and Lindstrom, Eva and Jonsson, Erik G.},
  issn         = {0885-6222},
  keyword      = {antipsychotic drugs,concomitant medication,schizophrenia,retrospective,poly-pharmacy,lifetime},
  language     = {eng},
  number       = {4-5},
  pages        = {322--331},
  publisher    = {John Wiley & Sons},
  series       = {Human Psychopharmacology: Clinical and Experimental},
  title        = {Concomitant medication of psychoses in a lifetime perspective},
  url          = {http://dx.doi.org/10.1002/hup.1209},
  volume       = {26},
  year         = {2011},
}